Showing 1 - 2 results of 2 for search 'O. Dalgard', query time: 0.01s Refine Results
  1. 1
    O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

    O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study by G. Dore, J. Grebely, F. Altice, A.H. Litwin, O. Dalgard, E.J. Gane, O. Shibolet, A. Luetkemeyer, R. Nahass, C.Y. Peng, B. Conway, D.M. Iser, H.C. Huang, I.N. Gendrano, M. Kelly, P. Hwang, M. Robertson, J. Wahl, E. Barr, H.L. Platt

    Published 2017
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

    O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study by J. Grebely, O. Dalgard, B. Conway, E. Cunningham, P. Bruggmann, B. Hajarizadeh, J. Amin, P. Marks, S. Quiene, T.L. Applegate, T. Swan, J. Byrne, M. Lacalamita, A. Dunlop, J. Bruneau, M.E. Hellard, G.V. Matthews, J. Powis, D. Shaw, M.C. Thurnheer, M. Weltman, I. Kronborg, C. Cooper, J.J. Feld, C. Fraser, A. Litwin, J. Dillon, P. Read, E. Gane, G.J. Dore

    Published 2017
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: